Fenwick, CraigTurelli, PriscillaDuhoo, YoanLau, KelvinHerate, CécileMarlin, RomainLamrayah, MyriamCampos, JérémyEsteves-Leuenberger, LineFarina, AlexRaclot, CharlèneGenet, VanessaFiscalini, FlurinCesborn, JulienPerez, LaurentDereuddre-Bosquet, NathalieContreras, VanessaLheureux, KyllianRelouzat, FrancisAbdelnabi, RanaLeyssen, PieterLévy, YvesPojer, FlorenceStahlberg, HenningLe Grand, RogerTrono, DidierPantaleo, Giuseppe2023-10-232023-10-232023-10-23202310.1016/j.jinf.2023.10.008https://infoscience.epfl.ch/handle/20.500.14299/201881Due to the rapid evolution of SARS-CoV-2 to variants with reduced sensitivity to vaccine-induced humoral immunity and the near complete loss of protective efficacy of licensed therapeutic monoclonal antibodies, we isolated a potent, broad-spectrum neutralizing antibody that could potentially provide prophylactic protection to immunocompromised patient populations.ACE2 mimetic; Neutralizing antibodies; Omicron; SARS-CoV-2; Variants of concern.text::journal::journal article::research article